Abarelix
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
ozanimod
S1P1,5 receptor modulator · Immunomodulator
S1P1,5 receptor modulatorImmunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AbarelixSevereDatabaseDDInter
- AbataceptSevereDatabaseDDInter
- AbemaciclibSevereDatabaseDDInter
- AbirateroneSevereDatabaseDDInter
Mechanism
Irreversible activator of S1PRs, causing irreversible downregulation of S1P signaling, thereby reducing the egress of lymphocytes from lymphoid tissue and disrupting the targeting of circulating lymphocytes to the CNS. Has high affinity for S1P1R and S1P5R.
Indications
relapsing-remitting msulcerative colitismoderate-to-severe ulcerative colitis (in patients who have failed biological therapies)relapsing forms of multiple sclerosis
Dosing
- Adult
- The dosage is titrated from 0.23 mg in the first 4 days to 0.46 mg in days 5 to 7 and 0.92 mg/day thereafter.
Pharmacokinetics
Peak effect
Peak plasma levels occur in 6 to 8 h.
Half-life
Plasma t1/2 of the parent drug is approximately 21 h; the t1/2 of the effect is approximately 11 days.
Metabolism
Extensive metabolism of the parent compound produces a series of active metabolites with similar specificity for S1P1R and S1P5R.
Contraindications
- fetal risk
- pregnancy
Side effects
Common
increased risk of infectionmacular edemacutaneous malignanciesupper respiratory infectionelevation of hepatic transaminasesbradyarrhythmia/atrioventricular conduction delaysorthostatic hypotensionurinary tract infectionback painhypertension
Serious
- first dose effects: bradycardia, decreased atrioventricular conduction, increased qtc interval
- ms may worsen if withdrawn
Drug interactions
Abatacept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Abemaciclib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Abiraterone
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adenosine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Afatinib
Severe
Database
Drug interaction classified as: others
Source: DDInter
Aflibercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alefacept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alemtuzumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alfuzosin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about ozanimod
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team